Insights Into Non-small Cell Lung Cancer (NSCLC)

Perspectives of community physicians from across the US on the drivers in treatment decisions in the management of lung cancer

Northeast – August 20, 2022

Faculty Chair

Narjust Duma, MD

Dana-Farber Cancer Institute, Boston, MA, USA

Midwest – September 16, 2022

Faculty Chair

Corey Langer, MD

University of Pennsylvania, Philadelphia, PA, USA

Northwest – November 18, 2022

Faculty Chair

Sushil Bhardwaj, MD

Good Samaritan Hospital, Suffern, NY, USA

More Information

  • Philadelphia, PA
  • New Jersey, Pennsylvania, Massachusetts, Maine, Connecticut, New York

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Report

Start discovering the insights

View Report


  • A moderated roundtable discussion focusing on the management and current use of treatment options for EGFR-mutant NSCLC in the community setting
  • Disease state and data presentations were developed in conjunction with a national or regional oncology expert


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.